Argenica's ARG-007 Shows Strongest Benefits in Severe Ischemic Stroke, AI Re-analysis Reveals
New data from an AI-driven re-analysis of Phase 2 clinical trial results for Argenica Therapeutics' neuroprotective drug, ARG-007, has indicated its strongest benefits are observed in more severe cases of ischemic stroke.
Ischemic stroke, the most common type, occurs when a blood clot or fatty deposit obstructs blood flow to the brain. Discovered by Prof Bruno Meloni, ARG-007 aims to protect brain cells and reduce cell death after a stroke or other brain injuries.
AI-Driven Re-analysis Uncovers Key Benefits
Argenica reported that when stroke severity was standardized using an AI tool, ARG-007 demonstrated potential to improve functional independence in patients with substantial brain injury upon hospital presentation.
The re-analysis showed statistically significant improvements in functional outcomes. It also found significantly lower follow-up volumes of brain tissue death for participants with more severe stroke who received ARG-007 compared to a placebo.
Validation and Addressing Unmet Needs
Dr. Liz Dallimore, Argenica's Managing Director, stated that reduced brain tissue death signifies neuroprotection and validates ARG-007's mechanism of action. She expressed optimism about the analysis from Brainomix, a company specializing in stroke data and imaging analysis.
Dr. Dallimore highlighted that severe acute ischemic stroke patients represent a high unmet medical need, often experiencing poorer outcomes following thrombectomy (clot removal).
ARG-007's demonstrated efficacy for these patients suggests its potential as the first adjunctive neuroprotective therapy to improve outcomes for this group.
The Role of AI and Future Development
The AI-enabled precision analysis, approved by the United States Food and Drug Administration, accurately classifies trial participants based on initial stroke severity.
Argenica plans to progress to the next stage of development, designing a more targeted Phase 2b clinical trial for ARG-007.